logo

Human Insulin Drugs And Delivery Devices Market Size (2024 - 2029)

The market size for human insulin drugs and delivery devices is projected to experience significant growth due to the increasing global prevalence of type 1 diabetes and the rising demand for effective diabetes management solutions. This growth is driven by factors such as sedentary lifestyles and unhealthy dietary habits, which contribute to the rising incidence of diabetes. Advancements in technology have led to the development of innovative insulin delivery systems, such as insulin pumps and continuous glucose monitoring devices, enhancing patient care and management. The expanding diabetic population and the need for improved insulin therapies and delivery methods present opportunities for collaboration among pharmaceutical companies, medical device manufacturers, and healthcare providers to enhance the quality of life for individuals with diabetes.

Home Market Analysis Healthcare Research Device Drug Combination Research Drug Filled Devices Research Insulin Biosimilars Industry Market Size

Market Size of Human Insulin Drugs And Delivery Devices Industry

Human Insulin Drugs and Delivery Devices Market Summary
Study Period 2018 - 2029
Market Size (2024) USD 67.45 Billion
Market Size (2029) USD 80.99 Billion
CAGR (2024 - 2029) 3.73 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Human Insulin Drugs and Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Human Insulin Drug and Delivery Device Market Analysis

The Human Insulin Drugs And Delivery Devices Market size is estimated at USD 67.45 billion in 2024, and is expected to reach USD 80.99 billion by 2029, growing at a CAGR of 3.73% during the forecast period (2024-2029).

Diabetes is generally considered a lifestyle-related disease. Over time, with the increase in population around the world, the incidences of the disease have increased outrageously. Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes. Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. 

The global increase in the population affected by type 1 diabetes has spurred significant growth in the insulin drugs and device market. Type 1 diabetes, characterized by the body's inability to produce insulin, affects millions of individuals worldwide, and its prevalence is on the rise. Factors such as sedentary lifestyles, unhealthy dietary habits, and genetic predispositions contribute to this upward trend.

With the expanding diabetic population, there is a growing demand for insulin medications and delivery devices to manage the condition effectively. Insulin remains the cornerstone of treatment for type 1 diabetes, as well as for some individuals with type 2 diabetes who require insulin therapy. As a result, pharmaceutical companies are investing in research and development to innovate new insulin formulations and delivery systems that offer improved efficacy, convenience, and safety for patients.

Moreover, advancements in technology have led to the development of insulin pumps, continuous glucose monitoring (CGM) systems, and artificial pancreas devices, which provide more precise insulin dosing and better glycemic control. These innovations have transformed diabetes management, empowering patients to lead more flexible and active lifestyles while reducing the risk of hypoglycemia and other complications.

The increasing prevalence of type 1 diabetes, coupled with advancements in insulin therapies and delivery devices, is expected to continue driving the growth of the insulin drugs and device market in the years to come. This growth presents opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers to collaborate in delivering innovative solutions that improve the quality of life for individuals living with diabetes.

Insulin Drugs and delivery devices are necessary for type-1 diabetes patients because their body doesn't produce insulin internally, type-2 diabetes patients also need insulin, particularly those who have difficulty controlling their diabetes with oral medications.

Human Insulin Drug and Delivery Device Industry Segmentation

The hormone class of drugs includes human insulin. In place of the insulin that the body ordinarily produces, human insulin is used. It assists in the movement of blood sugar into different bodily tissues, where it is used as an energy source. It also prevents the liver from generating additional sugar. The human insulin drug and delivery device market is segmented by type, device type, and geography. The report offers the value (in USD) and volume (in units) for the above segments. 

By Drug
Basal or Long Acting Insulins
Lantus (Insulin glargine)
Levemir (Insulin detemir)
Tresiba (Insulin degludec)
Toujeo (Insulin glargine)
Basaglar (Insulin glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin glargine biosimilars
Human insulin biosimilars
By Device
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Geography
North America
United States
Canada
Rest of North America
Europe
Germany
United Kingdom
France
Russia
Spain
Italy
Rest of Europe
Asia-Pacific
Australia
India
China
Japan
Malaysia
South Korea
Thailand
Philippines
Vietnam
Indonesia
Rest of the Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle-East and Africa
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of the Middle-East and Africa
Need A Different Region Or Segment?
Customize Now

Human Insulin Drugs And Delivery Devices Market Size Summary

The human insulin drugs and delivery devices market is poised for steady growth, driven by the increasing prevalence of diabetes globally. As diabetes becomes more widespread, particularly type 1 diabetes, the demand for insulin medications and delivery systems is on the rise. This demand is further fueled by lifestyle changes and genetic factors contributing to the disease's prevalence. Despite insulin being a cornerstone treatment for diabetes for over nine decades, access and affordability remain significant challenges, with a substantial portion of the population still unable to obtain necessary insulin. The market is characterized by ongoing research and development efforts aimed at innovating insulin formulations and delivery devices, such as insulin pumps and continuous glucose monitoring systems, which enhance patient care and lifestyle flexibility.

North America leads the market, despite high insulin prices, due to the lack of alternative treatments and the ongoing need for insulin among diabetic patients. The market is highly consolidated, with major players like Novo Nordisk, Sanofi, and Eli Lilly dominating the landscape. Recent collaborations and advancements, such as the development of automated insulin dosing systems, highlight the industry's focus on improving treatment efficacy and patient outcomes. The introduction of biosimilar insulin products is expected to alleviate some cost burdens, potentially expanding access to more patients. As the market continues to evolve, opportunities for innovation and collaboration among pharmaceutical companies, medical device manufacturers, and healthcare providers are expected to drive further growth and improve the quality of life for individuals with diabetes.

Explore More

Human Insulin Drugs And Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Drug

      1. 2.1.1 Basal or Long Acting Insulins

        1. 2.1.1.1 Lantus (Insulin glargine)

        2. 2.1.1.2 Levemir (Insulin detemir)

        3. 2.1.1.3 Tresiba (Insulin degludec)

        4. 2.1.1.4 Toujeo (Insulin glargine)

        5. 2.1.1.5 Basaglar (Insulin glargine)

      2. 2.1.2 Bolus or Fast Acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 2.1.2.2 Humalog (Insulin lispro)

        3. 2.1.2.3 Apidra (Insulin glulisine)

        4. 2.1.2.4 FIASP (Insulin aspart)

        5. 2.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Combination Insulins

        1. 2.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 2.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 2.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 2.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 2.1.5 Biosimilar Insulins

        1. 2.1.5.1 Insulin glargine biosimilars

        2. 2.1.5.2 Human insulin biosimilars

    2. 2.2 By Device

      1. 2.2.1 Insulin Pumps

        1. 2.2.1.1 Insulin Pump Devices

        2. 2.2.1.2 Insulin Pump Reservoirs

        3. 2.2.1.3 Insulin Infusion sets

      2. 2.2.2 Insulin Pens

        1. 2.2.2.1 Cartridges in reusable pens

        2. 2.2.2.2 Disposable insulin pens

      3. 2.2.3 Insulin Syringes

      4. 2.2.4 Insulin Jet Injectors

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Rest of North America

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Russia

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Italy

        7. 2.3.2.7 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 Australia

        2. 2.3.3.2 India

        3. 2.3.3.3 China

        4. 2.3.3.4 Japan

        5. 2.3.3.5 Malaysia

        6. 2.3.3.6 South Korea

        7. 2.3.3.7 Thailand

        8. 2.3.3.8 Philippines

        9. 2.3.3.9 Vietnam

        10. 2.3.3.10 Indonesia

        11. 2.3.3.11 Rest of the Asia-Pacific

      4. 2.3.4 Latin America

        1. 2.3.4.1 Brazil

        2. 2.3.4.2 Mexico

        3. 2.3.4.3 Rest of Latin America

      5. 2.3.5 Middle-East and Africa

        1. 2.3.5.1 Saudi Arabia

        2. 2.3.5.2 Iran

        3. 2.3.5.3 Egypt

        4. 2.3.5.4 Oman

        5. 2.3.5.5 South Africa

        6. 2.3.5.6 Rest of the Middle-East and Africa

Human Insulin Drugs And Delivery Devices Market Size FAQs

The Human Insulin Drugs And Delivery Devices Market size is expected to reach USD 67.45 billion in 2024 and grow at a CAGR of 3.73% to reach USD 80.99 billion by 2029.

In 2024, the Human Insulin Drugs And Delivery Devices Market size is expected to reach USD 67.45 billion.

Human Insulin Market Report Snapshots

Human Insulin Drug and Delivery Device Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)